Nebulized Gadolinium-Based Nanoparticles: A Theranostic Approach for Lung Tumor Imaging and Radiosensitization
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Lung cancer is the most common and most fatal cancer worldwide. Thus, improving early diagnosis and therapy is necessary. Previously, gadolinium-based ultra-small rigid platforms (USRPs) were developed to serve as multimodal imaging probes and as radiosensitizing agents. In addition, it was demonstrated that USRPs can be detected in the lungs using ultrashort echo-time magnetic resonance imaging (UTE-MRI) and fluorescence imaging after intrapulmonary administration in healthy animals. The goal of the present study is to evaluate their theranostic properties in mice with bioluminescent orthotopic lung cancer, after intrapulmonary nebulization or conventional intravenous administration. It is found that lung tumors can be detected non-invasively using fluorescence tomography or UTE-MRI after nebulization of USRPs, and this is confirmed by histological analysis of the lung sections. The deposition of USRPs around the tumor nodules is sufficient to generate a radiosensitizing effect when the mice are subjected to a single dose of 10 Gy conventional radiation one day after inhalation (mean survival time of 112 days versus 77 days for irradiated mice without USRPs treatment). No apparent systemic toxicity or induction of inflammation is observed. These results demonstrate the theranostic properties of USRPs for the multimodal detection of lung tumors and improved radiotherapy after nebulization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design considerations for tumour-targeted nanoparticles
Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2009.314 · Cited by 754
Driscoll, K. E. (2000) · Toxicological Sciences · doi:10.1093/toxsci/55.1.24 · Cited by 578
Targeted delivery of nanoparticles for the treatment of lung diseases
Azarmi, S., Roa, W. H., & Löbenberg, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.006 · Cited by 440
Cytotoxicity and oxidative stress induced by different metallic nanoparticles on human kidney cells
Pujalté, I., Passagne, I., Brouillaud, B., Tréguer, M., Durand, E., Ohayon-Courtès, C., & L'Azou, B. (2011) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-8-10 · Cited by 398
Nishanth, R. P., Jyotsna, R. G., Schlager, J. J., Hussain, S. M., & Reddanna, P. (2011) · Nanotoxicology · doi:10.3109/17435390.2010.541604 · Cited by 216
Cited by
Emerging Nanotechnology and Advanced Materials for Cancer Radiation Therapy
Song, G., Cheng, L., Chao, Y., Yang, K., & Liu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201700996 · Cited by 771
Biodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials
Bourquin, J., Milosevic, A., Hauser, D., Lehner, R., Blank, F., Petri‐Fink, A., & Rothen‐Rutishauser, B. (2018) · Advanced Materials · doi:10.1002/adma.201704307 · Cited by 461
Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization
Xie, J., Gong, L., Zhu, S., Yong, Y., Gu, Z., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201802244 · Cited by 415
Nanotechnology approaches for inhalation treatment of lung diseases
Kuzmov, A., & Minko, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.024 · Cited by 352
Liu, Y., Zhang, P., Li, F., Jin, X., Li, J., Chen, W., & Li, Q. (2018) · Theranostics · doi:10.7150/thno.22172 · Cited by 335
Metadata
- Authors
- Dufort, S., Bianchi, A., Henry, M., Lux, F., Le Duc, G., Josserand, V., Louis, C., Perriat, P., Crémillieux, Y., Tillement, O., & Coll, J.-L.
- Venue
- Small
- Publisher
- Wiley
- Published
- 2014-09-08
- Volume
- 11
- Issue
- 2
- Pages
- 215-221
- ISSN
- 1613-6810 (ISSN-L)
- OpenAlex
- W2157185978
- Cited by
- 113
- References
- 5
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.